今年，这份全球商界女性领袖的权威榜单迈入第28个年头。这份榜单既揭晓了当下最具有影响力的领导 者，也展示了未来有望攀登更高峰的潜力者。 "全球最具影响力的商界女性榜单"历来以数据为导向，依据高管所在企业规模、运营状况或损益表进行 评选，而今年的评选更是强化了数据维度。《财富》杂志首次采用更复杂的评分系统，除了基于业务指 标（涵盖12个月和三年周期数据），还结合高管的影响力、创新能力、职业轨迹以及为改善业务所做的 努力等维度为候选人赋值。该系统更倾向于首席执行官群体，因此，部分担任其他高管职位的上榜者在 榜单上的排名较往年有所下滑。 随着更多女性执掌举足轻重的企业，这份榜单的竞争变得更加激烈。今年排名前三位的分别是：蝉联榜 首的通用汽车公司首席执行官玛丽·巴拉（Mary Barra）、埃森哲首席执行官朱莉·斯威特（Julie Sweet） 和花旗集团首席执行官简·弗雷泽（Jane Fraser）。此外，还有来自沃尔玛、Netflix等全球顶尖企业的资 深领导者。 略超半数的上榜女性在美国工作，美国在推动女性登上企业最高层方面仍然大幅领先其他国家；其余48 位上榜者来自其他国家，覆盖19个国家和地区。紧随美国之后 ...

Core Viewpoint - Sanofi has announced the acquisition of Vigil Neuroscience, Inc., enhancing its neurology pipeline with a focus on developing treatments for Alzheimer's disease, specifically through the investigational drug VG-3927 [1][5]. Group 1: Acquisition Details - Sanofi will acquire all outstanding common shares of Vigil for $8 per share, totaling an equity value of approximately $470 million on a fully diluted basis [8]. - Vigil's shareholders will also receive a contingent value right (CVR) entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927 [8]. - The acquisition is expected to close in Q3 2025, subject to customary conditions including shareholder approval and regulatory clearances [9]. Group 2: Strategic Importance - This acquisition aligns with Sanofi's strategic focus on neurology and aims to address critical unmet needs in Alzheimer's treatment, where current therapies do not halt or reverse disease progression [4][2]. - The acquisition follows a $40 million strategic investment made by Sanofi in Vigil in June 2024, which included rights to negotiate for VG-3927 [5]. Group 3: Scientific Rationale - VG-3927 is an oral small molecule TREM2 agonist, which is expected to enhance the neuroprotective function of microglia in Alzheimer's disease [1]. - Activation of TREM2 is believed to improve microglial response to injury, potentially preventing neural degeneration associated with neurodegenerative diseases [3].

Investment Rating - The industry view for European banks has been raised to Attractive from In-Line [8][30][31] Core Insights - With risks to European growth receding, there is increased confidence that yield steepening will hold and net interest income (NII) growth will resume in 2026 [1][2][32] - The report estimates a 10% compound annual growth rate (CAGR) for earnings per share (EPS) from 2024 to 2027, which is not currently reflected in the 9x price-to-earnings (P/E) ratio [1][3][30] - The sector is expected to experience a trough in NII in the second half of 2025, followed by a 3-4% growth starting in 2026, with potential upside if loan growth accelerates [3][6][30] Summary by Sections Economic Outlook - Post US-China de-escalation, risks to European growth have diminished, leading to a maintained assumption of 1.5% ECB rates, with expectations of 25-50 basis points higher steepening than previously estimated [2][14][32] Earnings and Valuation - The report indicates that the sector is trading at the lower end of the historical P/E range of 8-13x, despite improved cost efficiency, lower credit risk, and less leverage compared to pre-global financial crisis (GFC) levels [4][30] - The average price targets imply an 18% upside for Euro Area and UK banks, compared to a mere 3% upside for the wider market [5][30] Strategic Recommendations - The report highlights a preference for longer duration/high deposit beta names, with upgrades for AIB and BOI to Equal-weight, and ABN also upgraded to Equal-weight [6][31][37] - Top picks include Commerzbank, Lloyds, Santander, and Soc Gen, reflecting a strategic focus on banks with better growth prospects [6][9][31]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

One of the largest Spanish lenders, Banco Santander, S.A. (SAN) , is undertaking several steps to streamline operations and pivot toward high-growth markets in Europe and the Americas. In sync with this, on May 5, the company announced the sale of approximately 49% stake in its Polish banking business, Santander Bank Polska S.A., to Austrian bank Erste Group for €6.8 billion ($7.7 billion). In addition, Erste Group will acquire 50% of Santander Polska's asset management business (TFI), which is not currentl ...

I recommend holding Santander Brasil (NYSE: BSBR ) shares after the release of its Q1 2025 results. This article is a continuation of my initial coverage article published on May 6, 2024, with a sell recommendation at the time.More than 5 years of experience in equity analysis in LatAm. We provide our clients with in-depth research and insights to help them make informed investment decisions.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, an ...

Group 1: Santander's Sale and Partnership - Santander is selling approximately 49% of Santander Polska's share capital and 50% of its Polish asset management business to Erste Group for $7.9 billion [1][2] - The deal includes a partnership where Santander will provide Erste access to its payment system, allowing both banks to explore opportunities in payments, particularly with Santander Polska post-completion [1][2] Group 2: Corporate and Investment Banking Collaboration - Santander and Erste are forming a corporate and investment banking partnership to leverage each other's regional strengths, offering local solutions and market insights to corporate and institutional clients through a referral model [3] - This partnership aims to facilitate seamless client interactions and service offerings [3] Group 3: Economic Outlook and Strategic Focus - Santander's Executive Chair, Ana Botín, highlighted the bank's focus on helping clients manage volatility related to U.S. tariffs and geopolitical uncertainty, which has contributed to a decline in the five-year growth forecast for the world economy to 3.1%, the lowest in 16 years [4] - The bank is leveraging its global scale and diversification as stabilizers in the current economic environment, anticipating continued profitability growth by 2025 [5] Group 4: Importance of Real-Time Payments - Research indicates that offering real-time payments is crucial for banks to attract and retain small and medium-sized business (SMB) clients, with many SMBs willing to pay fees for instant payment advantages [6][7] - Specifically, 88% of the smallest SMBs, those with annual revenues of less than $100,000, would be willing to pay a percentage fee for instant payments [7]

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

After underperforming for so long, it is nice to see Banco Santander, S.A. ( NYSE: SAN ) doing much better these days. Even by the standards of European financials, this bank has been an exceptional performer so far this year, returning over 60% in dollarI like to take a long term, buy-and-hold approach to investing, with a bias toward stocks that can sustainably post high quality earnings. Mostly found in the dividend and income section. Blog about various US/Canadian stocks at 'The Compound Investor', and ...

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The Genera ...